contagi
bovin
pleuropneumonia
cbpp
remain
major
cattl
diseas
africa
seriou
socioeconom
consequ
erad
requir
develop
improv
vaccin
knowledg
diseas
caus
agent
mycoplasma
mycoid
subsp
mycoid
biotyp
small
coloni
mmmsc
progress
significantli
last
year
open
new
area
vaccin
design
advanc
achiev
understand
protect
immun
respons
mmmsc
infect
immunopatholog
mechan
allow
pathogen
escap
host
immun
respons
base
sequenc
genom
studi
virul
factor
metabol
pathway
unravel
lead
identif
potenti
mmmsc
vaccin
candid
base
find
review
present
scientif
strategi
design
multicompon
subunit
vaccin
mucos
deliveri
promis
approach
effici
longterm
protect
vaccin
prevent
cbpp
r
contagieus
bovin
rest
une
maladi
majeur
de
bovin
en
afriqu
avec
de
son
le
de
vaccin
ce
derni
re
le
connaiss
de
cett
maladi
comm
de
lagent
pathog
ne
respons
mycoplasma
mycoid
subsp
mycoid
biotyp
small
coloni
mmmsc
ont
largement
ouvrant
la
voie
de
nouvel
approch
vaccinal
ce
ont
dan
la
de
immunitair
protectric
face
mmmsc
ainsi
que
de
immunopathologiqu
permett
mmmsc
la
de
de
plu
au
et
de
certain
facteur
de
virul
et
cycl
de
mmmsc
ont
permett
lidentif
de
candidat
vaccinaux
potentiel
partir
de
ce
cett
revu
une
scientifiqu
pour
le
de
vaccin
sousunitair
multicompos
ad
mucosal
comm
lapproch
la
plu
prometteus
pour
de
vaccin
protecteur
long
term
contr
la
ppcb
r
contagi
bovin
pleuropneumonia
cbpp
remain
one
major
cattl
diseas
africa
caus
mycoplasma
mycoid
subsp
mycoid
biotyp
small
coloni
mmmsc
cbpp
respons
heavi
econom
loss
due
mortal
loss
weight
reduc
work
abil
fertil
recent
studi
evalu
total
econom
cost
cbpp
africa
direct
indirect
product
loss
diseas
control
cost
million
euro
accur
data
requir
effici
epidemiolog
surveil
network
howev
lack
cbpp
includ
offic
intern
de
epizooti
oie
list
patholog
requir
offici
declar
http
wwwoieint
infect
countri
thu
exclud
intern
trade
cbpp
erad
twentieth
centuri
world
except
limit
area
europ
asia
base
program
combin
slaughter
control
cattl
movement
vaccin
howev
africa
sanitari
measur
use
contin
success
erad
cbpp
impractic
sinc
cattl
rais
reli
nomad
transhum
diseas
report
countri
countri
http
bostwana
stamp
whole
cattl
popul
affect
zone
ultim
choic
veterinari
servic
vaccin
avail
vaccin
fail
stop
spread
diseas
strategi
prove
effici
enabl
bostwana
regain
freedom
statu
remain
expens
appli
african
countri
achiev
erad
diseas
africa
develop
improv
vaccin
remain
realist
approach
vaccin
current
use
low
efficaci
requir
annual
costli
vaccin
campaign
vaccin
made
freezedri
broth
cultur
live
attenu
mmmsc
strain
present
sever
limit
short
durat
immun
protect
although
longer
strain
compar
persist
side
effect
mainli
strain
sever
studi
suggest
possibl
improv
efficaci
combin
use
antibiot
chang
vaccin
formul
use
primeboost
strategi
howev
might
expens
insuffici
overcom
intrins
limit
vaccin
base
immunolog
knowledg
anoth
approach
could
reli
new
rout
vaccin
deliveri
inde
well
known
mucos
diseas
cbpp
mucos
deliveri
would
significantli
improv
efficaci
host
immun
respons
far
howev
approach
receiv
attent
deserv
therefor
need
improv
vaccin
could
overcom
vaccin
limit
trigger
longterm
protect
coupl
effect
surveil
system
control
anim
movement
would
repres
relev
tool
achiev
erad
cbpp
africa
proof
feasibl
trigger
longterm
protect
immun
respons
cbpp
vaccin
stem
observ
cattl
recov
mmmsc
infect
protect
new
mmmsc
infect
recov
cattl
therefor
succeed
control
mmmsc
infect
mount
appropri
immun
respons
also
retain
lymph
node
mmmscspecif
immun
memori
abl
trigger
anamnest
protect
respons
object
also
support
experi
made
willem
show
subcutan
inocul
cbppinfect
lymph
protect
cattl
mmmsc
challeng
find
demonstr
longterm
protect
immun
respons
mmmsc
natur
develop
probabl
also
vaccin
induc
cattl
ration
develop
optim
vaccin
requir
good
understand
immunolog
base
protect
infect
well
understand
immunopatholog
mechan
underli
diseas
identif
compon
pathogen
involv
aspect
recent
studi
led
improv
knowledg
cbpp
lead
defin
relev
vaccin
strategi
diseas
review
give
rapid
overview
recent
result
discuss
ration
strategi
develop
optim
subunit
vaccin
safeti
vaccin
paramount
live
vector
vaccin
although
power
rais
concern
regard
safeti
stabil
potenti
revers
virul
effect
presenc
preexist
immun
trend
vaccinolog
focus
design
safer
betterdefin
subunit
vaccin
vaccin
strategi
determin
protect
immun
paramet
trigger
immunopatholog
mechan
control
antigen
pathogen
includ
vaccin
object
vaccin
elicit
least
prime
relev
immun
respons
allow
vaccin
host
quickli
mount
efficaci
protect
respons
contact
new
infect
identifi
mmmscspecif
immun
protect
mechan
thu
major
prerequisit
develop
effici
vaccin
aim
recent
studi
implement
character
immun
respons
elicit
cattl
natur
mmmsc
infect
compar
analys
mmmscspecif
humor
cellular
immun
respons
perform
anim
recov
die
mmmsc
infect
cattl
recov
mmmsc
infect
known
develop
longterm
immun
character
mmmscspecif
immun
mechan
gener
therefor
primari
immun
respons
persist
region
lymph
node
recov
anim
thu
unravel
basi
immun
protect
cbpp
mmmscspecif
memori
respons
respons
protect
anamnest
respons
understand
mechan
oper
develop
memori
tcell
central
goal
develop
effect
vaccin
strategi
result
studi
reveal
cattl
recov
mmmsc
infect
compar
anim
acut
infect
character
stronger
persist
local
iga
respons
higher
mmmscspecif
tcell
respons
ifng
product
detect
blood
persist
respiratori
lymph
node
sever
month
infect
data
mmmscspecif
local
cellmedi
immun
respons
although
valuabl
unravel
complet
protect
mechan
cbpp
yet
avail
due
difficulti
assess
aspect
cattl
nevertheless
key
find
persist
mmmscspecif
ifngsecret
tcell
drain
lymph
node
recov
cattl
sever
month
infect
inde
studi
sever
viral
bacteri
diseas
indic
pool
effector
tcell
expand
activ
infect
memori
cell
remain
detect
infect
resolut
arm
immun
system
therefor
play
role
protect
cbpp
local
humor
respons
reli
secretori
iga
cellular
respons
base
tcell
type
consequ
repres
main
target
elicit
prime
vaccin
induct
expans
subset
mmmscspecif
memori
tcell
requir
goal
develop
longterm
protect
cbpp
cbpp
respiratori
diseas
whose
pathogen
gener
remain
restrict
lung
key
role
local
humor
respons
predict
immunoglobulin
inde
main
element
humor
respons
provid
protect
microbi
antigen
enter
mucos
surfac
repres
import
first
line
defens
invas
deeper
tissu
iga
respons
might
play
direct
role
inhibit
mmmsc
growth
colon
andor
block
yet
unknown
virul
factor
tcell
respons
also
expect
sinc
mmmsc
extracellular
pathogen
extracellular
pathogen
gener
taken
antigen
present
cell
apc
process
associ
class
ii
molecul
major
histocompat
complex
mhc
present
tlymphocyt
tcell
contribut
protect
cbpp
mainli
cytokin
network
includ
ifng
enhanc
phagocytosi
cell
kill
abil
promot
express
mhc
class
ii
molecul
thu
increas
host
cell
capac
antigen
process
epitop
present
tlymphocyt
protect
role
ifnginduc
antibodi
abl
promot
kill
neutrophil
cattl
also
expect
sinc
neutrophil
recruit
observ
cbpp
lung
lesion
besid
tcell
play
also
key
role
facilit
bcell
prolifer
classswitch
give
rise
antigenspecif
iga
mucos
effector
site
whether
cell
benefici
optim
iga
product
known
either
cell
combin
support
antigenspecif
iga
respons
base
find
cbpp
vaccin
abl
trigger
local
antibodi
respons
persist
tcellmedi
respons
select
mmmsc
compon
understand
immunopatholog
aspect
cbpp
also
import
step
ration
design
optim
vaccin
inde
stimul
vaccineinduc
protect
immun
respons
impli
host
still
maintain
abil
mount
effici
anamnest
respons
contact
mmmsc
infect
howev
mmmsc
appear
possess
effici
mechan
escap
host
immun
respons
suggest
abil
surviv
encapsul
lung
lesion
also
lymph
node
infect
cattl
character
immunomodulatori
properti
mmmsc
interact
bovin
immun
cell
analyz
vitro
thu
demonstr
viabl
mmmsc
abl
trigger
timedepend
apoptosi
bovin
blood
leukocyt
wherea
heatkil
mmmsc
effect
solubl
mmmscsecret
compon
appear
play
role
process
viabl
mmmsc
strongli
depress
mitogen
activ
cona
bovin
tcell
mmmscmediat
immunosuppress
effect
might
thu
allow
pathogen
escap
host
respons
vivo
diminish
abil
mount
immun
respons
antigen
challeng
although
studi
necessari
fulli
unravel
mechan
result
confirm
import
take
account
immunopatholog
aspect
diseas
ration
develop
vaccin
besid
immunosuppress
effect
tcell
respons
mmmsc
also
appear
abl
escap
innat
humor
host
respons
mmmsc
character
inde
presenc
polysaccharid
ps
extern
pseudocapsul
genom
sequenc
identifi
metabol
pathway
lead
synthesi
capsular
ps
pseudocapsul
shown
role
virul
protect
mmmsc
host
antibodi
respons
cell
phagocytosi
data
confirm
mmmsc
evolv
effici
way
escap
bovin
immun
respons
control
achiev
full
vaccin
efficaci
otherwis
impair
host
immun
system
innat
humor
cellular
exposur
mmmsc
infect
lead
ineffici
vaccineinduc
anamnest
respons
aim
elucid
mmmsc
compon
mediat
patholog
effect
help
identifi
critic
vaccin
candid
antigen
abl
control
mechan
thu
enhanc
vaccin
efficaci
screen
mmmsc
compon
genet
librari
sera
bronchoalveolar
lavag
taken
natur
mmmscinfect
cattl
alreadi
reveal
panel
igaand
protein
du
plessi
person
commun
sever
compon
membran
lipoprotein
lpp
might
central
role
interact
mmmsc
host
cell
inflammatori
reaction
besid
capac
lpp
elicit
humor
respons
strong
potenti
trigger
also
cellmedi
respons
major
role
earli
host
respons
report
protein
known
display
bcell
tcell
epitop
sever
vaccin
influenza
malaria
yersinia
pesti
base
type
antigen
similar
approach
select
mmmsc
vaccin
candid
current
undertaken
vitro
assess
abil
panel
antibodyinduc
mmmsc
antigen
elicit
mmmscspecif
tcell
respons
dedieu
unpublish
data
aim
capac
four
mmmsc
lpp
lppa
lppb
lppc
lppq
recal
vitro
cellular
immun
respons
lymphocyt
taken
three
mmmscinfect
cattl
evalu
result
show
lppa
mmmsc
protein
recogn
mmmscprime
lymphocyt
dedieu
submit
find
demonstr
mmmscinfect
cattl
besid
known
humor
respons
mmmsc
lppa
also
develop
lppaspecif
tcell
respons
mmmsc
lppa
highli
conserv
lipoprotein
might
retain
potenti
vaccin
candid
cbpp
due
abil
trigger
arm
host
immun
respons
time
howev
protect
efficaci
lppatrigg
immun
respons
evalu
besid
screen
mmmsc
compon
immunogen
anoth
approach
could
target
select
mmmsc
virul
factor
howev
contrast
pathogen
bacteria
virul
reli
mainli
adhesin
toxin
typic
virul
factor
identifi
genom
mmmsc
refer
strain
recent
publish
genom
mycoplasma
speci
complet
sequenc
might
due
small
genom
lead
mycoplasma
drastic
save
genet
resourc
reduc
essenti
function
life
mycoplasma
thu
adopt
parasit
mode
life
acquir
macromolecular
precursor
highenergi
compound
host
cell
genom
sequenc
compar
genom
studi
nevertheless
led
identifi
mmmsc
pathogen
mechan
glycerol
transport
system
lead
product
cytotox
h
well
metabol
pathway
phosphotransferas
system
sugar
transport
sever
atpbind
cassett
abc
transport
transfer
compon
phosphat
oligopeptid
repres
interest
target
vaccineinduc
antibodi
respons
aim
control
mmmsc
growth
virul
block
glycerol
transport
membran
protein
gtsabc
membraneloc
glycerophosph
oxidas
glpo
specif
antibodi
result
inde
inhibit
glycerol
uptak
glycerol
metabol
signific
reduct
h
product
cytolyt
activ
antibodi
respons
might
thu
control
mmmsc
growth
glycerol
metabol
presum
requir
triglycerid
synthesi
control
pathogen
also
achiev
sinc
h
consid
virul
factor
similarli
antibodi
respons
block
membran
compon
metabol
pathway
abc
transport
like
limit
mmmsc
growth
thu
host
infect
inde
due
drastic
parasit
mode
mmmsc
depend
abc
transport
scaveng
precursor
host
cell
therefor
screen
potenti
mmmsc
compon
abil
elicit
antibodi
respons
mainli
local
iga
function
role
limit
mmmsc
growth
virul
would
lead
promis
vaccin
candid
parallel
vaccineinduc
mmmscspecif
infgsecret
tcell
respons
also
need
therefor
mmmsc
compon
abl
prime
respons
also
includ
vaccin
candid
select
tcell
screen
describ
either
select
antibodyinduc
mmmsc
antigen
purifi
mmmsc
protein
final
select
mmmsc
vaccin
candid
includ
vitro
safeti
control
evalu
patholog
effect
inflammatori
potenti
major
characterist
pathogen
strategi
hope
lead
select
appropri
antigen
includ
safe
multicompon
subunit
vaccin
abl
trigger
immun
respons
reduc
bacteri
load
clinic
outcom
infect
also
control
immunopatholog
mechan
involv
diseas
thu
allow
establish
effici
innat
vaccineinduc
immun
respons
abl
clear
infect
mmmsc
maintain
mmmscspecif
immun
memori
nonrepl
antigen
purifi
protein
often
low
immunogen
major
challeng
effect
vaccin
protect
antigen
identifi
lie
therefor
formul
deliveri
first
choic
relev
deliveri
system
addit
immunostimul
molecul
allow
enhanc
modul
orient
host
immun
respons
major
import
select
effect
system
capabl
induc
signific
immun
respons
mucos
site
inde
cbpp
mmmsc
enter
initi
infect
mucos
respiratori
surfac
constitut
best
target
effect
vaccin
system
immun
larg
ineffect
provid
immun
mucos
surfac
mucos
surfac
choic
site
immun
fact
mucos
immun
induc
mucos
system
immun
mucos
immun
benefit
exist
common
mucos
immun
system
immun
mucos
induct
site
activ
mucos
band
tcell
migrat
site
home
mucos
effector
site
accordingli
although
intranas
deliveri
appear
relev
oral
rout
also
promis
may
offer
inexpens
need
needl
profession
health
care
infrastructur
requir
inject
prepar
cold
chain
conveni
way
vaccin
edibl
vaccin
effect
approach
demonstr
panel
vaccin
current
licens
mucos
deliveri
domest
anim
eg
vaccin
bhv
coronaviru
rotaviru
cattl
although
live
vector
vaccin
larg
panel
potent
adjuv
bacteri
toxin
cell
wall
compon
cpg
oligonucleotid
antimicrobi
peptid
deliveri
system
biodegrad
microspher
liposom
novasom
vlp
iscom
etc
avail
mucos
vaccin
deliveri
abl
induc
mucos
antibodi
cellular
immun
respons
studi
domest
anim
nevertheless
limit
potenti
mucos
immun
purifi
antigen
remain
unexploit
veterinari
medicin
experi
cattl
shown
potenti
cholera
toxin
e
coli
heatlabil
lt
enterotoxin
mucos
immunoadjuv
efficaci
oral
intranas
immun
microparticl
iscom
also
great
potenti
deliveri
antigen
mucosa
howev
two
experi
conduct
cattl
iscom
vaccin
cbpp
vaccin
deliv
parenter
fail
protect
anim
mmmsc
challeng
anoth
possibl
reason
failur
vaccin
base
either
whole
inactiv
mmmsc
cytotox
lppq
protein
contrast
oral
deliveri
pig
anoth
pathogen
mycoplasma
mycoplasma
hyopneumonia
includ
microspher
led
effect
protect
therefor
new
antigen
deliveri
system
might
offer
promis
approach
mucos
vaccin
deliveri
larg
anim
advanc
understand
protect
immun
respons
mmmsc
infect
provid
promis
opportun
ration
develop
improv
vaccin
protect
shown
requir
mmmscspecif
pulmonari
iga
activ
local
macrophag
stimul
mmmscspecif
ifngsecret
tcell
immunolog
arm
could
effect
target
mucos
vaccin
inde
induct
protect
secretori
iga
shown
effici
achiev
mucos
antigen
stimul
target
mucosaassoci
lymphoid
tissu
local
lymph
node
enhanc
prime
mmmscspecif
ifng
secret
tcell
adjuv
use
deliveri
system
allow
vaccin
antigen
present
apc
mhc
class
ii
pathway
object
could
achiev
use
microparticl
biodegrad
microspher
chitosan
liposom
iscom
etc
increas
host
cell
phagocytosi
antigen
uptak
mhc
class
ii
present
tcell
besid
abil
particul
system
also
elicit
local
iga
larg
demonstr
potenc
deliveri
vehicl
enhanc
incorpor
adjuv
coat
immunostimul
molecul
lectin
tolllik
receptor
ligand
would
reduc
quantiti
antigen
need
thu
cost
vaccin
variou
strategi
alreadi
evalu
enhanc
particul
vaccin
uptak
efficaci
select
appropri
system
cbpp
vaccin
depend
natur
select
mmmsc
antigen
immunolog
properti
avail
deliveri
system
howev
context
tropic
veterinari
diseas
final
object
vaccin
technolog
transfer
african
partner
local
product
criteria
taken
account
thermost
cost
effect
manufactur
process
energi
requir
etc
stringent
criteria
one
hope
due
rapid
progress
field
achiev
near
futur
final
choic
reli
preliminari
evalu
vitro
assay
efficaci
test
presenc
mmmsc
vaccin
candid
unfortun
small
anim
model
relev
cbpp
studi
cattl
experi
costli
requir
high
secur
facil
deal
tropic
diseas
therefor
although
fulli
relev
term
mucos
immun
vitro
cellular
assay
help
determin
capac
deliveri
system
effici
captur
bovin
apc
efficaci
trigger
dc
matur
epitop
present
mmmscspecif
tcell
respons
autolog
tcell
taken
recov
cattl
cattl
experi
permit
evalu
vaccineinduc
mucos
immun
protect
efficaci
cbpp
infect
object
efficaci
cbpp
vaccin
would
limit
mmmsc
colon
thu
reduc
host
infect
strong
inflammatori
process
typic
diseas
control
mmmscinduc
immunosuppress
maintain
respons
host
immun
system
stimul
mmmscspecif
immun
memori
respons
respons
case
new
antigen
encount
anamnest
protect
respons
aim
shown
immun
paramet
correl
protect
mucos
product
mmmscspecif
iga
persist
mmmscspecif
infgsecret
tcell
respons
accordingli
mmmsc
vaccin
candid
select
criteria
advanc
understand
cbpp
better
character
caus
agent
mmmsc
togeth
improv
knowledg
mucos
immunolog
vaccin
deliveri
system
offer
promis
approach
develop
effici
longterm
protect
mucos
vaccin
prevent
cbpp
mucos
subunit
vaccin
mmmsc
infect
hope
limit
shed
mmmsc
therebi
reduc
pathogen
load
environ
consequ
reduc
rate
herd
infect
transmiss
cbpp
herd
hope
therefor
avail
optim
vaccin
coupl
effect
surveil
system
stricter
control
anim
movement
allow
one
control
even
eventu
erad
cbpp
african
contin
